30/11/2015 00:49:39 Cookie Policy Free Membership Login

Tyratech (DI/S) Share Price - TYR

Share Name Share Symbol Market Type Share ISIN Share Description
Tyratech (DI/S) LSE:TYR London Ordinary Share USU890581080 COM SHS USD0.001 (DI / REGS)
  Price Change Price Change % Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00 +0.00% 2.63 2.25 3.00 2.63 2.63 2.63 40,000 07:59:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) RN NRN
Chemicals 3.0 -3.3 -1.9 - 0.53

Tyratech (DI/S) News, Charts, Forums & Trades

More Tyratech (DI/S) News
Tyratech (DI/S) Takeover Rumours

Tyratech (DI/S) Share Charts

1 Year Tyratech (DI/S) Chart

1 Year Tyratech (DI/S) Chart

1 Month Tyratech (DI/S) Chart

1 Month Tyratech (DI/S) Chart

Intraday Tyratech (DI/S) Chart

Intraday Tyratech (DI/S) Chart

Tyratech (DI/S) Discussions and Chat

Tyratech (DI/S) Forums and Chat

Date Time Title Posts
29/11/201519:44TyraTech - Putting Nature to Work1,710
21/7/201412:21Alan Reade, Chairman of TyraTech offers a discussion on TyraTech-
18/7/201408:15Pests For You?458

Add a New Thread

Tyratech (DI/S) Top Chat Posts

jxman: Cambridge post Friday 28th feb TyraTech starting to make its markScan the list of UK quoted stocks and there are numerous examples of the classic falling knife. However, there can be few cases to rival the share price demise as that of chemical company TyraTech Inc.Although based in the US, TyraTech is listed over here and, perhaps surprisingly, boasts the presence of Standard life and Legal & General among others as major shareholders.Currently at 32p, the company has somehow clawed itself back from the brink, having seen its share price collapse from close to £5 three years back.While much of the early excitement and momentum behind those heady days evaporated, there are now, nevertheless, signs of a company that is beginning to gain recognition across its field.Such pointers could be worth exploring further and perhaps suggest that TyraTech could now be an attractive, albeit speculative, punt.Although firmly cast in the chemical sector by being a developer and producer of pesticides, any alignment to the conventional producers can be quickly dismissed.This is because TyraTech's offerings are based on and derived from natural ingredients before being harnessed to target only invertebrate pests that attack crops as well as people and pets.This is good news from a number of angles, including effectiveness, but importantly safety, as the products are not harmful to humans or animals.Having secured its own patents on the technology, the company, which can be seen as an eco-tech pesticide producer, has established products derived from natural plant oils and which are subsequently formulated to attack and effectively destroy their targets.Although it has taken TyraTech longer than originally anticipated to make its mark, some notable deals suggest it could grab a piece of what is potentially a massive global market.The estimated worth of the combined pesticide market for domestic and agricultural customers is said to be worth a staggering $33bn.And here the company has already gained acceptance by being aligned to the world's largest pesticide player, Terminix. A deal is already in place whereby Terminix is marketing TyraTech's technology as SafeShield Natural, supplying customers across the US, Canada and Mexico. Set to run to at least 2017, it is complemented by another collaboration with the giant Kraft food company, where the latter is using TyraTech's technology within its exciting functional foods programme.These alliances, along with others such as Arysta Lifesciences and Natural Forces Inc., should help build up earnings momentum in the coming years.House broker Brewin Dolphin is forecasting profits for next year and has pencilled in £1.34m pre-tax, along with EPS of 2.5p.If TyraTech can achieve that and continue to attract further blue chip client interest, then the shares look worth a punt at current levels. Read more: http://www.cambridge-news.co.uk/Business/Private-Punter/TyraTech-starting-to-make-its-mark-02082011.htm#ixzz2ueltiABU
haroldthegreat: when you are there next ask the pharmacist how often they sell them and what feedback they get.ask which are their best selling lice products, they will have nothing to hide and will give you an honest answer. you can then post it here for others to read. if you ask a professional the reply you get will give you more accurate information than on a board. the share price should tell you what the market thinks. for the record i have not had one person ask me for it!. i have sold one pack because i got fed up with looking at them. i asked the patient to tell me how they found it and they never reported back.
michaelsadvfn: Interesting bit from the placing RNS.. Company took the opportunity to withdraw the exclusivity under this agreement and is now pursuing alternative commercialisation strategies, one of them being marketing the products under its own PureScience(TM) brand in 2016. Thruppence a share, disastrous share price performance & I can't see it getting any better anytime soon.
michaelsadvfn: Well after watching TYRU rise 20% today and TYR do nothing I picked up 100k TYR at silly prices. The current share price is below the price before half the world started selling VaMousse so even more of a bargain than it was a year ago. Ta very much Mr. Market.
michaelsadvfn: Results in June superg1. Don't expect any surprises, Tyratech isn't about 2014, it's about H2 '15 and more likely 2016. You either believe in the business or you don't. I do. I can't think of any other company that has gotten it's foot in so many doors in such a short space of time both across the USA and in the UK. These retailers all like what they have seen and believe it will sell otherwise they wouldn't stock the stuff in the first place. As ever, patience is key. Unfortunately there's not a lot of that around the AIM market hence the depressed share price.
nobbygnome: Seems like the announcement makes sense. As I said a while ago, it is all about Vamousse in the short term. In addition, the cash will reduce the chance of needing another fund raising, which is probably the most important thing in terms of the share price! It will be interesting to see the market reaction (if any). GLA Nobby
michaelsadvfn: Nice update. With the share price down by a third on this time last year there is plenty of room for a rerating here. I can't quite understand why this stock is so out of favour.
sidam: I will take it at face value that you are, as you say, looking as an investor - not a pain. So some answers and points. I assume that you were given the same answers as I was. Envance In answer to your earlier question about Envance and funding. I have looked through copies of the various presentations that I have but can not find, in those, hard copy evidence that AMVAC supply working capital etc to the Envance JV. I recollect that I obtained that information in a Q & A session with management. However, if you look at the report and accounts for 2013 on page 7 you will see that AMVAC have contributed an additional $1.75m to the JV. So it is pretty evident that AMVAC do finance it. - In this area you can take my word for it, assume I am correct because of page 7 or ask management. However, the Terminix branding agreement is not dead. The products are being sold through Home Depot and Walmart, but not all branches. I do not know if you use Waitrose. I do and there are 4 branches close by. Not all stock the same product. The larger one normally has a bigger range, but some products are stocked in the smaller branches, whilst not in the largest. I guess it is the catchment area and that applies to the US. So your statement that the Terminix deal was dead was incorrect. So was your surmise that because of this AMVAC would dump there holding. On trademarks it was explained to me that: I quote Envance is still using the ENVANCE trademark and name; it has simply refined and better classified the goods and services with which the mark will be used. This is common practice in US trademark law. Vamousse - if you look at page 11 of the recent presentation, you will see that you are correct, there are three products, Lice Treatment, Lice Prevention and Lice Elimination. However, you had said the Lyclear also had a shampoo and added that TYR had indicated that their's was the only one on the market. The vamouse shampoo is a preventative but the lyclear is a treatment. So TYR are correct. TYR has other product - Guardian and the range sold through Novartis. In my view, it is likely that products in the Novartis sold range have much the largest potential revenues. But that will take time with probable customer trials this year and the start of orders next. Is this a sleeper? Obviously not as it is at times quite volatile. It is also obvious that, like very many early stage companies (sales but not profits), the current market capitalisation is not justified by the current level of revenues and profits (losses). However, the company has superb management, some products with very large potential and significant USPs. Those points, in my view, will generate substantial profits over the next few years and a share price a multiple of the current level.
haroldthegreat: nobby you are obviously an expert in this field so i will wait for the rns that says sales have exceeded our expectations and the massive rise in the share price. all i can see is the decline in the share price over the last few weeks so the market is not as optimistic as you are.
sidam: Well - some good research from GMF. "More fund raising looks nailed on. That share prophets article looks way off for revenue this year." The certainly appear to have got the share prophets article correct. Their projection of revenues for the year now look to be well off the mark. On broker's estimates their number was much TOO LOW. Brokers are now saying revenues this year will be $6m, so H2 should be nearer $5m than $3 - 4m. But your statement on cash looks a bit wrong. AMVAC for some reason have exercised part of their warrant, but before that the brokers estimated $4m of cash at year end. A small fall next year, but back to over $4m in December 2016. Also, the brokers are now forecasting profits next year and decent EPS and, as above, cash generation in 2016. SO NO NEED FOR MORE MONEY! As I have said before, current trading does not justify the current share price, but 2016 certainly justifies a higher price and that is only the start. By the way, Superdrug and Boots only had it in some stores, but are increasing that number. Tesco and Sainsbury will start rollout now and there are more retailers in the pipeline. Management indicate that Walmart sales are higher than original expectations. Lice are not seasonal. Children can get them all the year around at School. I am in for the long term and I think I will make a very good return.

Tyratech (DI/S) Most Recent Trade

Trade Type Trade Size Trade Price Trade Date Trade Time Currency
O 40,000 2.35 27 Nov 2015 12:54:28 GBX

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 151130 00:49